GlobalData on MSN3d
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase III
UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...
Daily Express12d
Landmark UK drug trial called LION aims to maul the world's toughest cancers
A revolutionary new drug trial called LION aims to ravage the ... a cancer immunologist from the Cancer Research UK Manchester Institute, University of Manchester. With plans to recruit 89 ...
Clinical Trials Arena on MSN13d
Merck KGaA’s lupus drug fails in SLE cohort of Phase II trial
Merck KGaA’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but ...
The Pharma Letter3d
Eneboparatide met primary Phase III endpoint, says AstraZeneca
High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...
Applied Clinical Trials Online7d
Doravirine/Islatravir Regimen Shows Promise in Multiple Phase III Trials for the Treatment of HIV
The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...